Lipidomics in Major Depressive Disorder

Andreas Walther, Carlo Vittorio Cannistraci, Kai Simons, Claudio Durán, Mathias J. Gerl, S. Wehrli, Clemens KirschbaumFrontiers in Psychiatry 2018 · DOI

TL;DR

This systematic review highlights lipidomics as a promising, yet still developing, field for understanding Major Depressive Disorder (MDD). By analyzing the complete lipid profile of individuals, researchers are uncovering potential diagnostic biomarkers and novel therapeutic targets, moving towards a more personalized approach to MDD treatment.

What Problem Does This Paper Address?

Major Depressive Disorder (MDD) is a complex and heterogeneous psychiatric illness affecting millions worldwide, yet its diagnosis and treatment remain challenging. Current diagnostic methods rely heavily on subjective symptom reporting, leading to low reliability and a high rate of non-responders to standard treatments. The underlying pathophysiology of MDD is intricate, and a "single biomarker" approach has proven insufficient. This paper addresses the need for a more comprehensive understanding of MDD's biological underpinnings, exploring how the study of lipids (lipidomics) can contribute to identifying diagnostic signatures and therapeutic avenues.

Methods

This paper is a systematic review, meaning it synthesizes existing research rather than presenting new experimental data. The authors conducted a thorough search of PubMed/Medline, EMBASE, and PsycINFO databases using specific keywords for both human and rodent studies related to lipidomics and depression. They applied PRISMA guidelines for study selection, filtering out reviews, meta-analyses, case studies, and other non-primary research. The included studies utilized various lipidomic quantification methods, primarily targeted liquid chromatography-mass spectrometry and gas chromatography. The review then analyzes these studies for their biological interpretations and discriminative power for MDD classification.

Datasets

The paper does not introduce new datasets. Instead, it reviews findings from numerous studies that utilized various datasets, including:

  • Human studies: Samples from general populations, patients with coronary artery disease and depressive symptoms, patients with seasonal affective disorders, and MDD patients (current and remitted) compared to healthy controls. These datasets varied in size, from tens to over a thousand participants.
  • Rodent studies: Data from rodent models of depression, often induced by chronic stress paradigms (e.g., chronic restraint stress, chronic unpredictable stress) or treated with antidepressants.

Key Insights and Ideas

  • Lipidomics as a Systems Approach: The complexity of MDD necessitates a systems-level understanding, and lipidomics, by examining the entire lipid profile, offers a powerful way to achieve this, moving beyond single-biomarker limitations.
  • Lipid-Inflammation Connection: A recurring theme is the link between lipid alterations, particularly those involving polyunsaturated fatty acids like arachidonic acid (AA), and inflammatory processes, which are increasingly recognized as playing a role in MDD.
  • HPA Axis and Glucocorticoid Influence: The paper proposes a model where chronic stress leads to HPA axis hyperactivity, increasing glucocorticoid levels. These, in turn, can dysregulate lipid metabolism and contribute to inflammation, creating a cycle that may predispose individuals to MDD.
  • Potential for Diagnostic Biomarkers: While current predictive power is insufficient for clinical application, several studies have identified combinations of lipid species that show promise in differentiating between MDD patients and healthy controls, suggesting the development of combinatorial lipid biomarkers.
  • Rodent Models Offer Causal Insights: Rodent studies, while not directly translatable to humans, provide valuable insights into the causal relationships between stress, lipid changes, and depressive-like behaviors, offering potential targets for drug development.

Key Results

  • Inconsistent but Promising Findings: While specific lipid species identified as differential markers for MDD vary across studies, there's an emerging pattern of reduced phosphatidylcholines (PC), phosphatidylethanolamines (PE), and phosphatidylinositols (PI), alongside increased lysophosphatidylcholines (LPC), lysophosphatidylethanolamines (LPE), ceramides (Cer), triacylglycerols (TAG), and diacylglycerols (DAG) in depressed states.
  • Diagnostic Potential: One study reported a combinatorial lipid marker with an Area Under the Curve (AUC) between 0.855 and 0.931 for differentiating MDD from healthy controls, indicating good discriminative power.
  • Lipid-Inflammation Markers: Studies have identified phospholipids containing pro-inflammatory compounds (e.g., linoleic acid, AA) in patients with depressive symptoms, further supporting the lipid-inflammation link.
  • Antidepressant Effects: Rodent studies showed that antidepressant treatments could alter lipid profiles, sometimes indicating increased phospholipase A2 (PLA2) activity, which is involved in releasing fatty acids that can contribute to inflammation.

Limitations and Future Work

  • Cross-Sectional Nature: A major limitation acknowledged is the predominantly cross-sectional nature of human studies. Longitudinal studies are needed to understand how lipid profiles change with disease state and treatment response.
  • Inconsistent Results: The review highlights that differential lipid species identified for MDD are not always consistent across studies, necessitating replication in independent cohorts.
  • Insufficient Predictive Power: Currently, the predictive power of identified lipid biomarkers is insufficient for direct clinical application.
  • Standardization Needed: Lipid nomenclature is not yet fully standardized, which can complicate comparisons between studies.
  • Future Directions: The authors emphasize the need for longitudinal studies, further validation of identified lipid markers, and the integration of computational psychiatry approaches to enhance predictive power. They also suggest exploring lipid pathway enrichment analyses to uncover underlying mechanisms and identify novel drug targets for precision medicine in MDD.

Summary updated

Abstract

Omic sciences coupled with novel computational approaches such as machine intelligence offer completely new approaches to major depressive disorder (MDD) research. The complexity of MDD's pathophysiology is being integrated into studies examining MDD's biology within the omic fields. Lipidomics, as a late-comer among other omic fields, is increasingly being recognized in psychiatric research because it has allowed the investigation of global lipid perturbations in patients suffering from MDD and indicated a crucial role of specific patterns of lipid alterations in the development and progression of MDD. Combinatorial lipid-markers with high classification power are being developed in order to assist MDD diagnosis, while rodent models of depression reveal lipidome changes and thereby unveil novel treatment targets for depression. In this systematic review, we provide an overview of current breakthroughs and future trends in the field of lipidomics in MDD research and thereby paving the way for precision medicine in MDD.
BibTeX
@inproceedings{walther2018lipidomics,
  author = {Andreas Walther and Carlo Vittorio Cannistraci and Kai Simons and Claudio Durán and Mathias J. Gerl and S. Wehrli and Clemens Kirschbaum},
  title = {{Lipidomics in Major Depressive Disorder}},
  booktitle = {Frontiers in Psychiatry},
  year = {2018},
  doi = {10.3389/fpsyt.2018.00459},
}
Figure